PIK3CA

(redirected from PI3K)
Also found in: Acronyms.

PIK3CA

A gene on chromosome 3q26.3 that encodes the 110-kDa catalytic subunit of phosphatidylinositol 3-kinase, which uses ATP to phosphorylate phosphatidylinositol, phosphatidylinositol4P and phosphatidylinositol(4,5)P2.
 
Molecular pathology
PIK3CA is oncogenic and been implicated in cervical cancers.
Mentioned in ?
References in periodicals archive ?
MTT, K252a, LY294002 and U0126 (Sigma, USA); rh[beta]-NGF (Pepro Tech, CA, USA); Rabbit polyclonal antibodies directed against TrkB, phospho-TrkB (Tyr515), PI3K, phosho-PI3K (Tyr467/199), Akt, phospho-Akt (Ser473), GSK30, phospho-GSK30 (S9), phosphoERK1/2 (Thr202/Tyr204), ERK1/2 (Bioworld Technology, USA); Rabbit polyclonal antibodies directed against CREB, phospho-CREB (Serl33) (Cell Signaling Technology, USA); Rabbit polyclonal antibodies directed against BDNF (Abeam, CA, USA).
326]Ile and the two silent polymorphs appeared to have no functional effect on the insulin stimulated PI3K activity.
Preliminary findings suggest that NRAS and PI3K alterations may also determine sensitivity to anti-EGFR agents.
The cultures were also treated for the phosphorylation and their epithelial outgrowth status of the signaling molecules after incubating with the specific PI3K inhibitor- LY294002 (25mM and 50mM concentration in DMSO).
Abbreviations: AM, alveolar macrophages; PA, Pseudomonas aeruginosa; GST, glutathione S transferase; YFP, yellow fluorescent protein; GFP, green fluorescent protein; PH, pleckstrin homology domain, Lyn, v-yes yamaguchi sarcoma related gene / protein; PI3K, phosphoinositol -3- kinase; Akt, protein kinase B; MHS, murine alveolar macrophage cell line from ATCC.
PI3K is a high profile anti-cancer target because it controls multiple key cellular functions associated with cancer progression.
Moreover, the interaction between PI3K and GR after activation by GA and 18[beta]GA remains unclear.
Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS)
Infinity pharma (INFI) - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity
Infinity will remain obligated to pay Millennium milestones related to the first two distinct PI3K product candidates that gain regulatory approval, comprising IPI-145.
A combined targeted therapy using both hedgehog and PI3K inhibitors could lead to a novel treatment for endocrine-resistant tumors in the future without use of chemotherapy," she said.